4-(3-phenylisoxazol-4-yl)benzenesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(3-phenylisoxazol-4-yl)benzenesulfonamide
• 英文别名: 4-(3-Phenyl-1,2-oxazol-4-yl)benzenesulfonamide
• 化学式: C₁₅H₁₂N₂O₃S
• 分子量: 300.338
• InChiKey: DLCFBVIPGPNHMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  94.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-溴苯磺酰胺 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 chloro(1,5-cyclooctadiene)(pentamethylcyclopentadiene)ruthenium(II) 、 四丁基氟化铵 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 1,2-二氯乙烷 为溶剂， 反应 1.08h， 生成 4-(3-phenylisoxazol-4-yl)benzenesulfonamide
  参考文献：
  名称：

  钌（ii）促进的带有炔烃的腈类氧化物的新型瓦尔德考昔衍生物的合成（1,3-偶极环加成反应）–合成和COX-2抑制活性†

  摘要：

  通过将腈与一系列十一个芳基炔烃进行1,3-偶极环加成反应，一步合成了一种新的基于valdecoxib的环氧合酶-2抑制剂，其中六个首次被描述。Ru（II）催化的应用优选导致3，4-二芳基取代的异恶唑的形成，而在与碱一起热加热下，有利于3，5-二芳基取代的模式。具有小的取代基（H和Me）的新的3,4-二芳基取代的异恶唑显示出高的COX-2抑制亲和力（IC 50= 0.042–0.073μM）和优异的选择性（COX-2 SI> 2000）。相反，3，5-二芳基取代的化合物几乎没有表现出COX活性。4-氟苯基取代基的引入导致保留了较高的COX-2亲和力，使这些化合物与可行的一步反应一起有望成为开发氟18标记的放射性示踪剂的候选物。

  DOI：

  10.1039/c7md00575j

文献信息

• [EN] SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION<br/>[FR] ISOXAZOLES SUBSTITUES UTILISABLES DANS LE TRAITEMENT D'INFLAMMATIONS
  申请人：G.D. SEARLE & CO.

  公开号：WO1996025405A1

  公开（公告）日：1996-08-22

  (EN) A class of substituted isoxazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula (III) whrein R7 is selected from hydroxyl, lower alkyl, carboxyl, halo, lower carboxyalkyl, lower alkoxycarbonylalkyl, lower alkoxyalkyl, lower carboxyalkoxyalkyl, lower haloalkyl, lower haloalkylsulfonyloxy, lower hydroxylalkyl, lower aryl (hydroxylalkyl), lower carboxyaryloxyalkyl, lower alkoxycarbonylaryloxyalkyl, lower cycloalkyl, lower cycloalkylalkyl, and lower aralkyl; and wherein R8 is one or more radicals independently selected from hydrido, lower alkylsulfinyl, lower alkyl, cyano, carboxyl, lower alkoxycarbonyl, lower haloalkyl, hydroxyl, lower hydroxyalkyl, lower haloalkoxy, amino, lower alkylamino, lower arylamino, lower aminoalkyl, nitro, halo, lower alkoxy, aminosulfonyl, and lower alkylthio; or a pharmaceutically-acceptable salt thereof.(FR) Cette invention concerne une classe de composés d'isoxazolyle substitué pouvant être utilisés dans le traitement d'inflammations et de troubles liés à des inflammations. Les composés suscitant un intérêt particulier sont représentés par la formule (III), dans laquelle R7 est choisi parmi hydroxyle, alkyle inférieur, carboxyle, halo, carboxyalkyle inférieur, alcoxycarbonylalkyle inférieur, alcoxyalkyle inférieur, carboxyalcoxyalkyle inférieur, haloalkyle inférieur, haloalkylsulfonyloxy inférieur, hydroxylalkyle inférieur, aryle(hydroxylalkyle) inférieur, carboxyaryloxyalkyle inférieur, alcoxycarbonylaryloxyalkyle inférieur, cycloalkyle inférieur, cycloalkylalkyle inférieur et aralkyle inférieur; et R8 représente un ou plusieurs radicaux choisis indépendamment parmi hydrido, alkylsulfinyle inférieur, alkyle inférieur, cyano, carboxyle, alcoxycarbonyle inférieur, haloalkyle inférieur, hydroxyle, hydroxyalkyle inférieur, haloalcoxy inférieur, amino, alkylamino inférieur, arylamino inférieur, aminoalkyle inférieur, nitro, halo, alcoxy inférieur, aminosulfonyle et alkylthio inférieur. Cette invention concerne également les sels de ces composés acceptables sur le plan pharmaceutique.

  本发明涉及一类取代的异噁唑基化合物，用于治疗炎症和与炎症相关的疾病。特别感兴趣的化合物由公式（III）定义，其中R7选自羟基，较低的烷基，羧基，卤素，较低的羧基烷基，较低的烷氧羰基烷基，较低的烷氧基烷基，较低的羧氧基烷氧基烷基，较低的卤代烷基，较低的卤代烷基磺酰氧基，较低的羟基烷基，较低的芳基（羟基烷基），较低的羧基芳氧基烷基，较低的烷氧羰基芳氧基烷基，较低的环烷基，较低的环烷基烷基和较低的芳基烷基；R8是一个或多个基团，独立选择自氢，较低的烷基亚砜基，较低的烷基，氰基，羧基，较低的烷氧羰基，较低的卤代烷基，羟基，较低的羟基烷基，较低的卤代烷氧基，氨基，较低的烷基氨基，较低的芳基氨基，较低的氨基烷基，硝基，卤素，较低的烷氧基，氨基磺酰基和较低的烷硫基；或其药学上可接受的盐。
• SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION
  申请人：G.D. SEARLE & CO.

  公开号：EP0809636A1

  公开（公告）日：1997-12-03
• COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS
  申请人：Reiley Pharmaceuticals, Inc.

  公开号：EP3242688B1

  公开（公告）日：2020-01-29
• COXIB-DERIVED CONJUGATE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Reiley Pharmaceuticals, Inc.

  公开号：US20220133918A1

  公开（公告）日：2022-05-05

  Compounds derived from celecoxib and valdecoxib, and methods of use thereof, are disclosed. The compounds are useful for, inter alia, identifying and localizing the site of pathology and/or inflammation responsible for the sensation of pain in a patient; for identifying the sites of primary, secondary, benign, or malignant tumors; and for diagnosing infection or confirming or ruling out suspected infection. The compounds contain a radioactive agent which permits imaging. The compounds concentrate at sites of increased cyclooxygenase expression, such as areas of increased COX-2 expression, thus revealing the sites of increased prostaglandin production, which is correlated with pain and inflammation, and correlated with tumor presence and/or location. Identifying areas of increased COX expressing can also aid in screening for infections, assessing efficacy of diagnosis and treatment of rheumatoid arthritis, and assessing the need for treatment with opioid drugs.
• [EN] COX-2-TARGETING, PLATINUM-CONTAINING CONJUGATES AND THEIR USE IN THE TREATMENT OF TUMORS AND CANCERS<br/>[FR] CONJUGUÉS CONTENANT DU PLATINE ET CIBLANT COX-2, ET UTILISATION DE CES DERNIERS DANS LE TRAITEMENT DE TUMEURS ET DE CANCERS
  申请人：REILEY PHARMACEUTICALS INC

  公开号：WO2016111834A1

  公开（公告）日：2016-07-14

  The present disclosure provides platinum-containing conjugates that selectively target and kill tumor/cancer cells. The conjugates contain a moiety that selectively targets COX-2, which is overexpressed by a broad range of tumor/cancer cells. The present disclosure provides conjugates that selectively target and kill tumor/cancer cells. The expression of cyclooxygenase II (COX-2) is upregulated in many benign and malignant tumor/cancer cells. In some embodiments, the conjugates comprise a COX-2-targeting moiety and a platinumcontaining antitumor agent. The term "antitumor agents" includes antitumor agents and anticancer agents. In some embodiments, the COX-2-targeting moiety comprises a non-steroidal anti-inflammatory drug (NSAID). In certain embodiments, the COX-2-targeting moiety comprises a COX-2-selective inhibitor.